Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.

Carolyn TallonBenjamin J BellMedhinee M MalvankarPragney DemeCarlos Nogueras-OrtizErden ErenAjit G ThomasKristen R HollingerArindom PalMaja MustapicMeixiang HuangKaleem ColemanTawnjerae R JoeRana RaisNorman J HaugheyDimitrios Kapogiannis Barbara S Slusher

Published in: Translational neurodegeneration (2023)

PDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice.

Keyphrases

mouse model
cerebrospinal fluid
high glucose
signaling pathway
diabetic rats
cognitive decline
high fat diet induced
multiple sclerosis
adipose tissue
drug induced
metabolic syndrome
skeletal muscle
insulin resistance
mild cognitive impairment